A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

Status: complete

This study is a multi-center, randomized, open label, Phase III clinical trial for advanced Nasopharyngeal Carcinoma(NPC) Patients. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving an infusion of a person's cytotoxic T cells (CTL) that have been treated in the laboratory may help the body build an effective immune response to kill tumor cells. Giving combination chemotherapy together with laboratory-treated T cells may kill more tumor cells. This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by adoptive T-cell therapy would improve clinical outcome for patients with advanced nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3 T-cell therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from 30 hospital centers across Asia and the United States. This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38 patients at the National Cancer Centre, Singapore. This trial produced the best published 2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with advanced NPC who received autologous EBV-specific CTL. Kindly see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled "Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma".

Inclusion Criteria

Metastatic or locally recurrent EBV-positive, non-keratinizing and/ or undifferentiated NPC* who do not have curative options such as chemo-radiation or surgery *Subjects will be enrolled based on confirmed histology diagnosis of the NPC
Radiologically measurable disease as per RECIST 1.1
Human Immunodeficiency Virus (HIV) negative* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening
Bilirubin <2 x upper limit of normal (ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) <3 x ULN
Calculated creatinine clearance (CRCL) ≥40 mL/min. Glomerular Filtration Rate (GFR) is calculated based on Cockcroft-Gault method.
Normal corrected calcium levels
Absolute neutrophil count >1200/mm3, hemoglobin (Hb) ≥10 g/dL and platelets ≥100,000/mm3
Male or female
Age ≥ 18 years or according to local legal age of consent
Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) ≤2
Written informed consent
Life expectancy >6 months Key

Exclusion Criteria

Severe concomitant illness i.e. chronic obstructive pulmonary disease (COPD), ischemic heart disease (IHD), active congestive cardiac failure (CCF), active angina pectoris, uncontrolled arrhythmia, uncontrolled hypertension
HIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 4 weeks of screening
Pregnant or lactating females
Refuse of use of contraception during trial (both male and female patients)
Investigational therapy less than one month prior to study entry
Pre-existing peripheral neuropathy (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] ≥2)
Central nervous system metastasis
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis and T1] or any cancer curatively treated >3 years prior to study entry
Positive hepatitis B surface antigen (HBsAg) results
Known history of hepatitis C and recovery status has not been determined at time of screening
Prior anti-cancer treatment for metastatic or locally recurrent disease, EXCEPT: For metastatic or locally recurrent disease, localised palliative radiotherapy is allowed. For locally recurrent disease, the following treatment is allowed
Prior radiotherapy with curative intent
Prior chemo-radiotherapy with curative intent
Adjuvant chemotherapy
Localised palliative radiotherapy Prior chemotherapy must be > 6 months before screening
Severe intercurrent infections
Prior immunotherapy for metastatic or locally recurrent disease The following is allowable: • Adjuvant immunotherapy/ biologics Prior adjuvant immunotherapy/ biologics must be > 6 months before screening

330 patients will be randomized after their eligibility status has been fully determined

and informed consent has been obtained. Patients will be randomly allocated to receive

either Arm A (Gemcitabine and Carboplatin (GC) x 4* cycles and EBV-specific CTL) or Arm B

(GC x 6 cycles alone) in a 1:1 ratio using a stratified block randomization scheme. The

stratification variables are country and disease stage (metastatic vs locally recurrent).

*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon

discretion of Investigator, if EBV-specific CTL infusions are not available in time for

the 1st scheduled infusion.

After randomization, patients in Arm A will have their peripheral blood taken for the

establishment of cytotoxic T cell line and EBV transformed lymphoblastoid cell line

(CTL). Within two weeks of enrollment, patients will commence combination GC chemotherapy

for a total of 4 cycles. Patients in Stage 2 of study will receive the EBV-specific CTL

immunotherapy.

As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs,

will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000

mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help